Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients

Table 2

Biochemical parameters and bone turnover markers at baseline.

	Alendronate; (𝑛=5)	Control; (𝑛=7)	𝑃 value
Ca (mg/dL)	9.2±0.4	9.4±0.5	NS
P (mg/dL)	3.5±0.6	3.3±0.8	NS
wPTH (pg/mL)	28.5±9.7	34.8±12.4	NS
BAP (IU/L)	10.3±2.3	13.0±5.1	NS
1, 25-(OH)2vitD	40.3±11.6	40.0±17.6	NS
NTx	21.6±12.3	20.0±5.6	NS
eGFR (mL/min/1.73 m^2)	41.2±9.9	35.1±6.9	NS

Ca: serum calcium; P: serum phosphate; wPTH: serum whole parathyroid hormone; BAP: serum bone-specific alkaline phosphatase; 1, 25-(OH)₂vitD: serum 1, 25-dihydroxycholecalciferol; NTx: serum N-terminal telopeptides of bone-specific type I collagen; eGFR: estimated glomerular filtration rate; NS: not significant.